Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

US Patent 9161935 · Granted Oct 20, 2015

Estimated economic value: $122,219,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of rasagiline for the treatment of restless legs syndrome2025
Compounds for treatment of eye diseases associated with excessive vascularisatio2025
Oral octreotide therapy and contraceptive methods2024
Treatment of ocular inflammatory diseases using laquinimod2023
Treatment of ocular inflammatory diseases using laquinimod2023
Compounds for treatment of eye diseases associated with excessive vascularisatio2022
Oral octreotide therapy and contraceptive methods2021
Oral octreotide administered in combination with other therapeutic agents2020
Parenteral formulations of rasagiline2016
Use of rasagilline for the treatment of restless legs syndrome2015
Treatment of multiple sclerosis with combination of laquinimod and fingolimod2014
Treatment of multiple sclerosis with combination of laquinimod and fingolimod2014